{"filings":[{"id":92354,"accession_number":"0001104659-26-057524","cik":1346830,"company_name":"Tvardi Therapeutics, Inc.","ticker":"TVRD","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tvardi Q1 net loss narrows to $6.8M; TTI-109 data due June, TTI-101 HCC data 2H 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $6.8M ($0.73 per share) vs $9.6M ($3.72) in Q1 2025; R&D spend rose to $4.9M.","Cash, cash equivalents and ST investments $25.0M at March 31, 2026; runway through Q4 2026.","TTI-109 Phase 1 healthy volunteer topline data and development strategy expected June 2026.","TTI-101 Phase 2 HCC topline data on track for 2H 2026; IPF fibrosis score reduction 9.4% vs 2.4% placebo.","TTI-109 is a next-generation STAT3 prodrug designed for improved tolerability vs TTI-101."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":31896568.363636363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103153,"accession_number":"0001104659-26-037724","cik":1346830,"company_name":"Tvardi Therapeutics, Inc.","ticker":"TVRD","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tvardi reports 2025 net loss $18.2M; cash to fund into Q4 2026; key clinical milestones ahead","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for 2025 was $18.2M ($2.46 basic EPS); cash $30.8M expected to fund operations into Q4 2026.","R&D expenses decreased to $18.0M in 2025 from $23.7M in 2024, driven by lower TTI-101 clinical costs.","Phase 2 IPF trial of TTI-101 showed 9.4% fibrosis reduction vs 2.4% placebo; IL-6 declined 4.5-fold.","Topline data from TTI-109 healthy volunteer study expected Q2 2026; TTI-101 HCC Phase 2 data in H2 2026.","G&A expenses rose to $8.7M in 2025 from $4.5M in 2024 due to merger-related professional fees."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":31896568.363636363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103152,"accession_number":"0001104659-26-024676","cik":1346830,"company_name":"Tvardi Therapeutics, Inc.","ticker":"TVRD","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Tvardi Therapeutics announces June 9, 2026 annual meeting; sets proposal deadlines","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting of stockholders scheduled for June 9, 2026.","Rule 14a-8 stockholder proposals for proxy inclusion must be received by March 16, 2026.","Advance notice for director nominations and other business under bylaws due March 16, 2026.","Universal proxy rule (Rule 14a-19) notices for director nominees due April 10, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":31896568.363636363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103151,"accession_number":"0001104659-26-004273","cik":1346830,"company_name":"Tvardi Therapeutics, Inc.","ticker":"TVRD","form_type":"8-K","filed_at":"2026-01-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Tvardi Therapeutics posts updated corporate presentation on website","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation available on company website as of January 16, 2026.","No financial or operational updates disclosed in the filing text.","Exhibit 99.1 appears incomplete; content not fully available for review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":31896568.363636363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119394,"accession_number":"0001104659-25-122615","cik":1346830,"company_name":"Tvardi Therapeutics, Inc.","ticker":"TVRD","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Tvardi grants retention stock options to CEO, CMO, CFO; adopts severance plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved one-time retention options: CEO Imran Alibhai 47,500, CMO John Kauh 17,500, CFO Dan Conn 17,500 shares.","Options vest 25% on Dec 16, 2026, then 36 equal monthly installments.","New Severance Plan provides cash severance, COBRA, and equity acceleration on qualifying termination with or without Change in Control.","CEO Alibhai eligible for 18 months salary plus 150% target bonus within Change in Control period; others 12 months salary plus 100% bonus.","Plan supersedes prior severance agreements; participation requires signed release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":31896568.363636363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119393,"accession_number":"0001104659-25-113901","cik":1346830,"company_name":"Tvardi Therapeutics, Inc.","ticker":"TVRD","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Tvardi Therapeutics posts updated corporate presentation on Nov 19, 2025; full details unavailable","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Corporate presentation is available on company's website as of November 19, 2025.","Exhibit 99.1 only contains header 'Overview November 2025' with no specific data provided in filing excerpt.","No financial or operational updates, guidance changes, or material events are disclosed in the available text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":31896568.363636363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119392,"accession_number":"0001104659-25-111310","cik":1346830,"company_name":"Tvardi Therapeutics, Inc.","ticker":"TVRD","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tvardi Q3 net loss $5.5M; IPF trial fails, HCC data due H1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net loss of $5.5M ($0.59/share), roughly flat YoY; cash $36.5M, runway into Q4 2026.","Phase 2 REVERT Liver Cancer (TTI-101) topline data expected H1 2026; interim showed activity.","TTI-109 healthy volunteer study started; results also H1 2026.","REVERT IPF trial preliminary data in October did not meet goals; further analysis underway.","R&D expenses $3.6M, down from $4.8M; G&A $2.3M, up from $0.9M."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":31896568.363636363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119391,"accession_number":"0001104659-25-098908","cik":1346830,"company_name":"Tvardi Therapeutics, Inc.","ticker":"TVRD","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Tvardi Therapeutics Phase 2 IPF trial misses endpoints; no benefit from TTI-101","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Trial did not meet goals; no statistically significant difference between TTI-101 and placebo on FVC change.","High discontinuation rates in TTI-101 arms (56.7% and 62.1%) vs placebo (10.3%), driven by GI adverse events, especially with nintedanib.","Placebo arm FVC decline lower than historical controls; at 12 weeks, mean FVC change: placebo -22.2 mL, 400mg -61.1 mL, 800mg -102.8 mL.","Cash of $41M as of June 30, 2025 expected to fund into Q4 2026; next-gen STAT3 inhibitor TTI-109 and HCC trial data on track for H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":31896568.363636363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135949,"accession_number":"0001104659-25-078665","cik":1346830,"company_name":"Tvardi Therapeutics, Inc.","ticker":"TVRD","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tvardi Therapeutics Q2 net income $4.2M; IPF Phase 2 topline data on track for Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $4.2M vs. net loss of $7.0M in Q2 2024; driven by $12.8M remeasurement gain on convertible notes.","Basic EPS of $0.51; diluted EPS loss of $1.00.","R&D expenses $5.8M (down $0.7M YoY); G&A expenses $3.1M (up $2.4M due to merger costs).","Cash, equivalents, and short-term investments $41.0M as of June 30, 2025; runway into Q4 2026.","REVERT IPF Phase 2 trial fully enrolled; topline data expected Q4 2025. IND for TTI-109 submitted to FDA in June 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":31896568.363636363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135948,"accession_number":"0001104659-25-067785","cik":1346830,"company_name":"Tvardi Therapeutics, Inc.","ticker":"TVRD","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Shaheen Wirk resigns from Tvardi Therapeutics board, no disagreement cited","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Shaheen Wirk resigned from the Board of Directors on July 8, 2025.","Resignation was not the result of any disagreement with the company.","Wirk had served as a board member since March 2024 and previously as a special advisor.","No replacement has been announced as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":31896568.363636363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152968,"accession_number":"0001104659-25-057524","cik":1346830,"company_name":"Tvardi Therapeutics, Inc.","ticker":"TVRD","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Tvardi Therapeutics posts updated corporate presentation; no specific new data disclosed in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company updated corporate presentation and posted it on investor relations website as of June 6, 2025.","Presentation may be used in conversations with analysts and investors; no material financial or operational updates provided.","Exhibit 99.1 content not fully available in this filing; no new guidance, trial results, or business developments detailed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":31896568.363636363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152967,"accession_number":"0001104659-25-052733","cik":1346830,"company_name":"Tvardi Therapeutics, Inc.","ticker":"TVRD","form_type":"8-K","filed_at":"2025-05-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Tvardi completes enrollment in Phase 2 IPF trial of TTI-101; topline data Q4 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed enrollment in REVERT IPF Phase 2 trial of oral STAT3 inhibitor TTI-101 for idiopathic pulmonary fibrosis.","Trial is randomized, double-blind, placebo-controlled; endpoints include safety and lung function (FVC).","Topline data from the REVERT IPF trial is anticipated in the fourth quarter of 2025.","TTI-101 targets STAT3, a central mediator of fibrotic signaling pathways."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":31896568.363636363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152966,"accession_number":"0001104659-25-047856","cik":1346830,"company_name":"Tvardi Therapeutics, Inc.","ticker":"TVRD","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","4.01","9.01"],"status":"ready","headline":"Tvardi completes merger with Cara, switches auditor to Deloitte, cash into 2H 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed merger with Cara Therapeutics; received ~$23.8M net cash; cash runway expected into 2H 2026.","Dismissed Ernst & Young as auditor; engaged Deloitte & Touche for FY 2025; no disagreements reported.","Phase 2 data for TTI-101 in IPF expected 2H 2025; IND for TTI-109 planned 1H 2025.","Phase 1 study of TTI-101 in advanced solid tumors published in Clinical Cancer Research."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":31896568.363636363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152964,"accession_number":"0001104659-25-047844","cik":1346830,"company_name":"Tvardi Therapeutics, Inc.","ticker":"TVRD","form_type":"8-K/A","filed_at":"2025-05-13T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"Tvardi Q1 2025 net loss $9.6M, cash burn $7.7M; going concern doubt persists","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss $9.6M ($0.50 dil EPS) vs $4.2M loss in Q1 2024; accumulated deficit $101.8M.","Revenue nil; operating expenses $4.35M (R&D $3.1M, G&A $1.2M).","Cash & equivalents $11.4M, short-term investments $10.9M at March 31; cash used in ops $7.7M.","Convertible notes $35.8M; other expense $5.5M from fair value change on notes.","Merger closed April 15, 2025 provided $23.8M cash; substantial doubt about going concern pre-merger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":31896568.363636363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152965,"accession_number":"0001104659-25-035121","cik":1346830,"company_name":"Tvardi Therapeutics, Inc.","ticker":"TVRD","form_type":"8-K","filed_at":"2025-04-15T23:59:59+00:00","items":["2.01","1.01","5.02","9.01","3.03","5.01","5.03","5.05","5.06","7.01","8.01"],"status":"ready","headline":"Cara-Tvardi merger closes, new company renamed Tvardi Therapeutics (TVRD)","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger completed April 15, 2025: Merger Sub merged into Tvardi, which became a wholly owned subsidiary.","Post-merger ownership: pre-Cara holders ~15.4%, pre-Tvardi holders ~72.0%, Convertible Note holders ~12.5% fully diluted.","1-for-3 reverse stock split effected; common stock begins trading as TVRD on Nasdaq on April 16, 2025.","Asset disposition of difelikefalin to CSL Vifor for $900K; Cara paid CSL Vifor $3M for future expenses.","Lead candidate TTI-101 in Phase 2 for IPF; unblinded data expected H2 2025; HCC data expected H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":31896568.363636363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152963,"accession_number":"0001104659-25-034220","cik":1346830,"company_name":"Tvardi Therapeutics, Inc.","ticker":"TVRD","form_type":"8-K","filed_at":"2025-04-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cara Therapeutics issues investor deck for pending merger with Tvardi (STAT3 fibrosis program)","summary_kind":"llm","event_type":"m_and_a","confidence":"medium","bullets":["Merger with Tvardi Therapeutics (STAT3 inhibitor developer for fibrosis) announced Dec 17, 2024; closing conditions remain.","Investor presentation shared with potential investors outlines Tvardi's clinical pipeline and post-combination strategy.","No new financial terms disclosed; forward-looking statements caution on risks related to closing timing and regulatory submissions.","Tvardi focuses on oral small-molecule STAT3 therapies for fibrosis-driven diseases with significant unmet need."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":31896568.363636363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152962,"accession_number":"0001104659-25-030583","cik":1346830,"company_name":"Tvardi Therapeutics, Inc.","ticker":"TVRD","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Cara stockholders approve all six merger proposals with Tvardi; Tvardi posts $29.4M net loss","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["All proposals passed: stock issuance for merger (2,088,293 for), equity plan, ESPP, reverse split (1:2-1:4), authorized shares increase to 150M, and advisory compensation.","Reverse stock split ratio between 1-for-2 and 1-for-4 to be mutually agreed by Cara and Tvardi boards before merger.","Tvardi audited 2024: net loss $29.4M (vs $17.3M in 2023), cash $31.6M, with going concern qualification.","Tvardi's lead candidate TTI-101 in Phase 2 for idiopathic pulmonary fibrosis and hepatocellular carcinoma.","Merger completion subject to customary closing conditions including Cara net cash of at least $18M at closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":31896568.363636363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171756,"accession_number":"0001104659-25-027233","cik":1346830,"company_name":"Tvardi Therapeutics, Inc.","ticker":"TVRD","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Cara issues supplemental disclosures for Tvardi merger after stockholder lawsuits","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received 13 demands and 2 lawsuits (filed Mar 5-6, 2025) claiming proxy omitted material info.","Combined company board to have 5 Tvardi designees, 1 Cara designee (Susan Shiff), 1 vacancy.","Piper Sandler valuation analyses updated with detailed peer comparisons and IPO precedent tables.","Cara denies violations but provides supplements to avoid litigation expense and merger disruption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":31896568.363636363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171755,"accession_number":"0001104659-25-004747","cik":1346830,"company_name":"Tvardi Therapeutics, Inc.","ticker":"TVRD","form_type":"8-K","filed_at":"2025-01-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Cara Therapeutics files investor presentation for proposed merger with Tvardi","summary_kind":"llm","event_type":"m_and_a","confidence":"low","bullets":["Furnishes investor presentation (Exhibit 99.1) for post-combination company with Tvardi, a STAT3-targeted fibrosis biopharma.","Merger announced Dec 17, 2024; pending regulatory and shareholder approvals; S-4 filed with preliminary proxy/prospectus.","Presentation is being shared with potential investors; no new financial terms or deal value disclosed in filing.","Forward-looking statements reference efforts to regain Nasdaq compliance on stockholders' equity requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":31896568.363636363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171754,"accession_number":"0001104659-25-004517","cik":1346830,"company_name":"Tvardi Therapeutics, Inc.","ticker":"TVRD","form_type":"8-K","filed_at":"2025-01-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nasdaq bid price compliance regained; equity compliance deadline extended to May 19","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cara regained Nasdaq minimum bid price compliance after 1-for-12 reverse stock split effective Dec 30; letter received Jan 16.","Stockholders' equity of $707k at Sep 30 below $2.5M minimum; extension granted to May 19, 2025.","Extension conditional on closing proposed merger with Tvardi, which is expected to meet initial listing criteria.","Company must also satisfy all applicable Nasdaq initial listing standards at merger close."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":31896568.363636363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188751,"accession_number":"0001104659-24-132481","cik":1346830,"company_name":"Tvardi Therapeutics, Inc.","ticker":"TVRD","form_type":"8-K","filed_at":"2024-12-30T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Cara Therapeutics effects 1-for-12 reverse stock split and reduces authorized shares from 200M to ~16.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective 5:00 p.m. ET Dec 30, 2024; trading on split-adjusted basis begins Dec 31, 2024.","Authorized common shares reduced from 200,000,000 to 16,666,667; par value unchanged.","No fractional shares issued; cash payment will be made in lieu of fractional shares.","Proportionate adjustments made to stock options, equity plan reserves, and exercise prices.","Stockholder-approved at June 4, 2024 annual meeting; board approved specific ratio Dec 19, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":31896568.363636363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188748,"accession_number":"0001104659-24-130803","cik":1346830,"company_name":"Tvardi Therapeutics, Inc.","ticker":"TVRD","form_type":"8-K/A","filed_at":"2024-12-20T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Cara Therapeutics files amended 8-K to correct investor presentation for proposed merger with Tvardi Therapeutics","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger agreement with Tvardi Therapeutics and merger sub was signed on December 17, 2024.","Asset Purchase Agreement with Vifor Fresenius Medical Care Renal Pharma for disposition of assets was signed on December 17, 2024.","Stockholder support agreements and lock-up agreements were filed with the SEC on December 17, 2024.","This amendment corrects formatting errors in the investor presentation originally filed on December 18, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":31896568.363636363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188750,"accession_number":"0001104659-24-129596","cik":1346830,"company_name":"Tvardi Therapeutics, Inc.","ticker":"TVRD","form_type":"8-K","filed_at":"2024-12-18T23:59:59+00:00","items":["1.01","5.01","5.02","8.01","9.01"],"status":"ready","headline":"Cara Therapeutics to Merge with Tvardi Therapeutics and Sell Difelikefalin Assets to CSL Vifor","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Cara enters Merger Agreement with Tvardi; pre-Merger Cara holders will own ~15.25%, Tvardi holders ~12.54%, convertible note holders ~72.21% of combined company.","Cara agrees to sell difelikefalin assets to CSL Vifor for $900,000 plus $3 million payment to CSL Vifor for estimated future expenses.","Tvardi CEO Imran Alibhai, Ph.D., will become CEO of combined company; Tvardi CFO Dan Conn to be CFO; existing Cara officers expected to depart.","Tvardi convertible notes of ~$28 million principal automatically convert into Cara common stock at closing; lock-up agreements restrict transfer for 180 days.","Support agreements from Cara holders representing ~1.0% of Cara stock and Tvardi holders representing ~97% of Tvardi capital stock to vote in favor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":31896568.363636363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188749,"accession_number":"0001104659-24-122099","cik":1346830,"company_name":"Tvardi Therapeutics, Inc.","ticker":"TVRD","form_type":"8-K","filed_at":"2024-11-22T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Cara Therapeutics gets Nasdaq deficiency for equity ($707K vs $2.5M min); also faces bid-price delisting risk","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity of $707,000 at Sep 30, 2024 is below Nasdaq's $2.5 million minimum.","Company has 45 days (by Jan 3, 2025) to submit a compliance plan; Nasdaq may grant up to 180-day extension.","Also has outstanding minimum bid price deficiency; must close at $1.00+ for 10 consecutive days by Jan 27, 2025.","Listing remains effective pending compliance; company evaluating options including reverse stock split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":31896568.363636363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205222,"accession_number":"0001104659-24-084911","cik":1346830,"company_name":"Tvardi Therapeutics, Inc.","ticker":"TVRD","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Cara Therapeutics gets Nasdaq extension to Jan 2025 to regain $1 bid price; stock moved to Capital Market","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq granted 180-day extension, until January 27, 2025, to meet minimum $1.00 closing bid price for 10 consecutive business days.","Company's common stock transferred from Nasdaq Global Market to Nasdaq Capital Market effective August 1, 2024.","If compliance not achieved by deadline, Nasdaq will delist; company may appeal to a Nasdaq Hearings Panel.","Company will monitor bid price and consider options including a reverse stock split to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":31896568.363636363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222095,"accession_number":"0001104659-24-072821","cik":1346830,"company_name":"Tvardi Therapeutics, Inc.","ticker":"TVRD","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Cara Therapeutics cuts workforce 70% after discontinuing NP program, explores strategic alternatives","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved streamlined operating plan and strategic alternatives after discontinuing NP program following KOURAGE-1 Part A results on June 12, 2024.","Workforce reduction of approximately 70%, substantially complete by June 30, 2024.","Expects approximately $2.6M in total charges for termination benefits, recognized in Q2 and Q3 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":31896568.363636363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222094,"accession_number":"0001104659-24-070914","cik":1346830,"company_name":"Tvardi Therapeutics, Inc.","ticker":"TVRD","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cara Therapeutics discontinues NP program after oral difelikefalin fails Part A of KOURAGE-1 study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Oral difelikefalin did not demonstrate meaningful clinical benefit at any dose vs. placebo in Part A of KOURAGE-1 study for notalgia paresthetica.","Company discontinues clinical program in NP and will explore strategic alternatives to maximize shareholder value.","Cash, cash equivalents, and marketable securities were approximately $70 million as of March 31, 2024.","Drug was well tolerated; safety profile similar to prior trials. Part A enrolled 214 patients across four arms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":31896568.363636363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222093,"accession_number":"0001104659-24-069625","cik":1346830,"company_name":"Tvardi Therapeutics, Inc.","ticker":"TVRD","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"CARA shareholders approve doubling authorized shares and authorize reverse stock split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common stock increased from 100M to 200M shares; 76.5% of votes in favor.","Board authorized to implement reverse stock split at ratio 1:4 to 1:12, with proportionate reduction in authorized shares.","Directors Susan Shiff and Helen Boudreau elected; advisory say-on-pay passed with 16.3M for vs 10.7M against.","Ernst & Young ratified as independent auditor for FY2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":31896568.363636363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222092,"accession_number":"0001104659-24-060529","cik":1346830,"company_name":"Tvardi Therapeutics, Inc.","ticker":"TVRD","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cara Therapeutics Q1 2024 net loss $0.56/shr, revenue $2.1M; NP data by end 2Q24","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $30.7M ($0.56/shr) vs $26.7M ($0.49) in Q1 2023; total revenue $2.1M down from $6.2M.","Cash & marketable securities $69.8M at March 31, 2024, down from $100.8M at Dec 31, 2023; ops used $30.5M.","KOURAGE 1 Part A topline NP results expected by end of Q2 2024; 214 patients enrolled, not powered for significance.","KORSUVA injection net sales $1.8M in Q1 2024; TDAPA expired March 31, now reimbursed via ESRD bundle.","Restructuring expenses $2.4M related to workforce reduction; R&D $22.0M vs $24.3M a year ago."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":2135000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":31896568.363636363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241623,"accession_number":"0001104659-24-037855","cik":1346830,"company_name":"Tvardi Therapeutics, Inc.","ticker":"TVRD","form_type":"8-K","filed_at":"2024-03-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cara Therapeutics CMO Joana Goncalves resigns effective April 16, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Joana Goncalves notified Company of resignation on March 19, 2024.","Departure is to pursue another opportunity and not related to any disagreement.","She will remain CMO through April 16, 2024, assisting in transition.","Duties will be assumed by other senior management team members."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":31896568.363636363,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}